Bacterial antimicrobial resistance (AMR)—which occurs when changes in bacteria cause the drugs used to treat infections to become less effective—has emerged as one of the leading public health threats of the 21st century. The Review on Antimicrobial Resistance, commissioned by the UK Government, argued that AMR could kill 10 million people per year by 2050.
Natureza® Develops a Transformative New Class of Antibiotics that Overcomes Bacterial Resistance. We have successfully shown these coated Fatty Acids work as effective antibiotics in in vitro and in vivo, with activity against some of the most drug resistant pathogens. Uniquely, bacteria exposed to them do not develop resistance.
Declining private investment and lack of innovation in the development of new antibiotics are undermining efforts to combat drug-resistant infections, says the World Health Organization (WHO). Two new reports reveal a weak pipeline for antibiotic agents. The 60 products in development (50 antibiotics and 10 biologics) bring little benefit over existing treatments and very few target the most critical resistant bacteria (Gram-negative bacteria).
The WHO has recognised a number of antibiotic-resistant pathogens as posing the greatest threat to human health. It further concluded that mortality and morbidity from resistant infections is on the rise globally, the clinical anti-bacterial pipeline remains insufficient, and the pipeline outlook remains bleak (WHO 2019).
During the Super Bowl, a representative of the pharmaceutical company Eli Lilly posted the on the company’s corporate blog that the average cost of bringing a new drug to market is $1.3 billion, a price that would buy 371 Super Bowl ads, 16 million official NFL footballs, two pro football stadiums, pay of almost all NFL football players, and every seat in every NFL stadium for six weeks in a row. This is, of course, ludicrous. The average drug developed by a major pharmaceutical company costs between $4-$11 billion.
Metabolic disrupters, phages, and other approaches are going to be needed to treat the broadest possible range of patients infected by bacterial pathogens resistant to multiple drugs. In 1924 President Coolidge's youngest son developed a blister on a toe playing tennis. The blister became infected with staph, and he died a week later at just 16 years old. Two decades later, penicillin could have saved him, but this drug is now useless against staph because of drug resistance, which has now become a broader crisis in medicine.
The advent of multidrug resistance among pathogenic bacteria is imperiling the worth of antibiotics, which have previously transformed medical sciences. The crisis of antimicrobial resistance has been ascribed to the misuse of these agents and due to unavailability of newer drugs attributable to exigent regulatory requirements and reduced financial inducements.
While medical research has helped us overcome many health threats, we now face a new type of crisis: Many dangerous bacteria are becoming resistant to the drugs meant to fight them. Healthcare professionals antibiotics to treat many forms of bacterial infection — from those that are mild to those that are potentially life threatening. For the most part, antibiotics have proved to be a crucial ally in the fight for health, but over the past few years, these drugs have begun to lose their footing in their confrontation with bacteria.
A report, Antibacterial agents in clinical development, analizes the antibacterial clinical development pipeline launched by WHO, shows a serious lack development new antibiotics to combat the growing antimicrobial resistance threat. Most of the drugs currently in the pipeline are modifications of existing classes of antibiotics and are only short-term solutions. The report found very few potential treatment options for antibiotic-resistant infections, including drug-resistant TB which kills about 250,000 annually.
The Review on Antimicrobial Resistance (AMR), was commissioned in July 2014 by the UK Prime Minister, who asked economist Jim O’Neill to analyse the global problem of rising drug resistance and propose concrete actions to tackle it internationally. The Review on AMR was jointly supported by the UK Government and Wellcome Trust, although operated with full independence from both. The final report and recommendations were published in the summer of 2016.